Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Zanzalintinib; Drug: Zanzalintinib-matched Placebo; Biological: Pembrolizumab Sponsors: Exelixis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials